bioAffinity Technologies, Inc.

NasdaqCM:BIAF Stock Report

Market Cap: US$8.0m

bioAffinity Technologies Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BIAF?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,520,8188.49%
Individual Insiders3,842,64121.5%
General Public12,543,30870%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.5%.

Top Shareholders

Top 25 shareholders own 29.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.08%
Steven Girgenti
1,088,918US$488.4k1.38%no data
4.89%
L1 Capital Pty. Limited
876,391US$393.1k0%0.01%
3.74%
Gary Rubin
669,203US$300.1k356%no data
3.63%
Roby Joyce
649,745US$291.4k0%no data
1.83%
Nathan Perlmutter
327,909US$147.1k0%no data
1.57%
Maria Zannes
280,259US$125.7k15.2%no data
1.46%
The Vanguard Group, Inc.
260,869US$117.0k0%no data
0.92%
Robert Anderson
163,936US$73.5k0%no data
0.67%
James Edwards
120,129US$53.9k5.42%no data
0.66%
Peter Knight
117,455US$52.7k0%no data
0.61%
Mohsin Meghji
109,737US$49.2k0%no data
0.61%
District 2 Capital LP
108,776US$48.8k0%0.64%
0.56%
Geode Capital Management, LLC
99,551US$44.6k14.2%no data
0.55%
Stuart Diamond
99,088US$44.4k0%no data
0.31%
Timothy Zannes
54,765US$24.6k18.7%no data
0.31%
Jamie Platt
54,748US$24.6k0%no data
0.26%
Sheaff Brock Investment Advisors, LLC
46,304US$20.8k132%no data
0.26%
Vivienne Rebel
46,228US$20.7k0%no data
0.23%
Xavier Reveles
41,943US$18.8k106%no data
0.16%
CapFinancial Partners, LLC, Asset Management Arm
27,885US$12.5k0%no data
0.1%
Michael Dougherty
18,578US$8.3k-77.9%no data
0.098%
State Street Global Advisors, Inc.
17,600US$7.9k0%no data
0.081%
Two Sigma Securities, LLC, Asset Management Arm
14,420US$6.5k0%no data
0.076%
Northern Trust Global Investments
13,662US$6.1k0%no data
0.074%
Citadel Advisors LLC
13,264US$5.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 04:19
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

bioAffinity Technologies, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group